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Summary
Regulator of G-protein signaling (RGS) proteins accelerate GTP hydrolysis by Gα subunits and are
thus crucial to the timing of G protein-coupled receptor (GPCR) signaling. Small molecule inhibition
of RGS proteins is an attractive therapeutic approach to diseases involving dysregulated GPCR
signaling. Methyl-N-[(4-chlorophenyl)sulfonyl]-4-nitrobenzenesulfinimidoate (CCG-4986) was
reported as a selective RGS4 inhibitor, but with an unknown mechanism of action (Roman et al.,
2007 Mol Pharmacol. 71:169−75). Here, we describe its mechanism of action as covalent
modification of RGS4. Mutant RGS4 proteins devoid of surface-exposed cysteine residues were
characterized using surface plasmon resonance and FRET assays of Gα binding, as well as single-
turnover GTP hydrolysis assays of RGS4 GAP activity, demonstrating that cysteine-132 within
RGS4 is required for sensitivity to CCG-4986 inhibition. Sensitivity to CCG-4986 can be engendered
within RGS8 by replacing the wildtype residue found in this position to cysteine. Mass spectrometry
analysis identified a 153 dalton fragment of CCG-4986 as being covalently attached to the surface-
exposed cysteines of the RGS4 RGS domain. We conclude that the mechanism of action of the RGS
protein inhibitor CCG-4986 is via covalent modification of Cys-132 of RGS4, likely causing steric
hinderance with the all-helical domain of the Gα substrate.
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1. Introduction
The single largest class of pharmaceuticals currently prescribed are those that target G protein-
coupled receptor (GPCR) signaling pathways [1,2]. Recently, members of the “regulator of G-
protein signaling” (RGS) protein superfamily have emerged as critical endogenous modulators
of GPCR signal transduction (reviewed in [3,4]). Via their conserved RGS domain that confers
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“GTPase-accelerating protein” (GAP) activity, RGS proteins deactivate heterotrimeric G-
protein α subunits and thereby attenuate GPCR signal transduction [5,6]. We and others have
speculated that small molecule RGS protein modulators should have clinical utility in
potentiating or inhibiting the actions of endogenous GPCR agonists (e.g., refs. [7,8]);
combining existing GPCR agonists with specific RGS domain inhibitors should potentiate
cellular responses and could also markedly increase specificity of action of existing drugs. In
particular, the diversity of RGS proteins with highly localized and dynamically regulated
distributions in the human brain makes them attractive targets for pharmacotherapy of central
nervous system disorders such as Parkinson's disease and opiate addiction (reviewed in [9,
10]).
Despite their obvious potential as vanguards of a novel pharmacotherapeutic strategy, few
reports currently exist of small molecule inhibitors of RGS protein action. Two groups have
recently described identifying inhibitors of the RGS protein/Gα interaction (BMS-195270,
CCG-4986), but the specific biochemical mechanism of action for each compound remained
unresolved in these initial studies [11,12]. Roman et al. identified CCG-4986 in a flow-
cytometric protein interaction assay as an inhibitor of RGS4 binding to the G-protein subunit
Gαo [12]. CCG-4986 inhibits the GAP activity of RGS4 in single-turnover GTP hydrolysis
and inactivates the action of recombinant RGS4 protein in inhibiting μ-opioid receptor
signaling by permeabilized C6 glioma cells; in contrast, Gα binding and inhibition of μ-opioid
receptor signaling by a related R4-subfamily RGS protein (RGS8) is unperturbed by the actions
of CCG-4986 [12]. Here, we describe biochemical, biophysical, and mass spectrometric
analyses of the interaction between CCG-4986 and RGS4, which support the conclusion that
this small molecule RGS inhibitor is a reactive modifier of a solvent-exposed cysteine present




374.82) was purchased from ChemBridge (San Diego, CA); identity and purity of CCG-4986
was confirmed by electrospray mass spectrometry (ESI-MS) conducted at the UNC-Duke
Michael Hooker Proteomics Core Facility. Unless otherwise noted, all reagents used were the
highest grade available from Sigma Aldrich (St. Louis, MO) or Fisher Scientific (Pittsburgh,
PA).
2.2 Protein expression and purification
Wildtype human RGS4 (amino acids 29−198; cloned as a hexahistidine-tagged fusion in
pSGC-LIC) was obtained from the Structural Genomics Consortium (Oxford, UK); point
mutations were made using QuikChange site directed mutagenesis (Stratagene, La Jolla, CA).
DNA encoding wildtype human RGS4 (amino acids 50−177) and wildtype RGS8 (amino acids
62−191), and point mutants thereof, were also subcloned into a Novagen (San Diego, CA) pET
vector-based prokaryotic expression construct (“pET-YFP-LIC-C”) using PCR and ligation-
independent cloning [13]. The resultant constructs encoded RGS4 as C-terminal fusions to
enhanced yellow fluorescent protein (hereafter described as YFP; Clontech, Mountain View,
CA) with an intervening 12 amino acid linker sequence (TSRGRMYTQSNA).
For expression of both hexahistidine-tagged and YFP-tagged RGS proteins, BL21(DE3) E.
coli were grown to an OD600nm of 0.7−0.8 at 37°C before induction with 0.5 mM isopropyl-
β-D-thiogalactopyranoside. After culture for 14−16 hours at 20°C, cells were pelleted by
centrifugation and frozen at −80°C. Prior to purification, bacterial cell pellets were resuspended
in N1 buffer (50 mM HEPES pH 8.0, 300 mM NaCl, 30 mM imidazole, 2.5% (w/v) glycerol).
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Bacteria were lysed at 10,000 kPa using pressure homogenization with an Emulsiflex (Avestin;
Ottawa, Canada). Cellular lysates were centrifuged at 100,000 × g for 30 minutes at 4°C. The
supernatant was applied to a nickel-nitrilotriacetic acid resin FPLC column (FF HisTrap; GE
Healthcare, Piscataway, NJ), washed with 7 column volumes of N1 then 3 column volumes of
30 mM imidazole before elution of RGS proteins with 300 mM imidazole. Eluted protein was
cleaved with tobacco etch virus (TEV) protease overnight at 4°C and dialyzed into low
imidazole buffer (N1 plus 5 mM DTT) before being passed over a second HisTrap column to
separate residual His6-RGS protein from untagged, cleaved RGS protein. The column flow-
through was pooled and resolved using a calibrated 150 ml size exclusion column (Sephacryl
S200; GE Healthcare) with S200 buffer (50 mM Tris pH 8.0, 250 mM NaCl, DTT 5 mM, 2.5%
(w/v) glycerol). Protein was then concentrated to approximately 1 mM, as determined by
A280 nm measurements upon denaturation in 8 M guanidine hydrochloride. Concentration was
calculated based on predicted extinction coefficient (http://us.expasy.org/tools/
protparam.html). RGS4 was prepared for MS analysis using S200 buffer without glycerol (“MS
Buffer”). Human RGS8 and RGS16 constructs were also provided by the Structural Genomic
Consortium and purified as described (RGS8: http://www.sgc.ox.ac.uk/structures/MM/
RGS8A_2ihd_MM.html, RGS16: http://www.sgc.ox.ac.uk/structures/MM/
RGS16A_2bt2_MM.html). C-terminally biotinylated Gαi1 and Gαi1-CFP fusion proteins were
prepared as described previously [14,15]. His6-GαoA was purifed as described [16].
2.3 Fluorescent and radiolabelled nucleotide single-turnover GTPase assays
BODIPYFL-GTP (Invitrogen; Carlsbad, CA) hydrolysis was measured and quantified using
single nucleotide binding-and-turnover assays as previously described [16]. Single turnover
[γ−32P]GTP hydrolysis assays were conducted using 100 nM Gαi1, 200 nM RGS4 protein, and
2 μM CCG-4986 as previously described [17]. Briefly, 100 nM Gαi1 was incubated for 10
minutes at 30°C with 1 × 106 cpm of [γ−32P]GTP (specific activity of 6500 dpm/Ci) in the
absence of free magnesium. Reaction was then chilled on ice for 1 minute prior to the addition
of 10 mM MgCl2 (final concentration) with or without added RGS protein (200 nM final) in
the presence or absence of 10-fold molar excess CCG-4986. Reactions were kept on ice and
100 μl aliquots were taken at 30 second intervals, quenched in 900 μl of charcoal slurry,
centrifuged, and 600 μl aliquots of supernatant counted via liquid scintillation as described
[17].
2.4 Surface plasmon resonance-based binding assays
Optical detection of surface plasmon resonance (SPR) was performed using a Biacore 3000
(Biacore Inc., Piscataway, NJ). Biotinylated Gαi1 was immobilized on streptavidin sensor chips
(Biacore) to densities of ∼6000 RU as previously described [15]. In pilot studies, CCG-4986
was observed to react with the biosensor surface, preventing us from obtaining high-quality
protein/protein interaction data in its presence (data not shown). To obviate this problem, we
removed excess CCG-4986 from RGS protein samples using rapid gel filtration. Specifically,
all proteins samples were first incubated for 3 minutes at room temperature in a 50 μl volume
containing 30 μM RGS protein with a 10-fold molar excess of CCG-4986 (or DMSO
equivalent) in the absence or presence of 10 mM DTT. RGS protein was then separated from
unbound compound and other low-molecular weight reagents by Sephadex G-25
chromatography (Illustra™ MicroSpin™ G-25 Column; GE Healthcare) via centrifugation for
1 minute at 735 × g. The flow through was then diluted in 250 μl of BIA running buffer (10
mM HEPES pH 7.4, 150 mM NaCl, 0.05% NP40, 100 μM GDP, 5 μM EDTA, 10 mM
MgCl2, 10 mM NaF, 30 μM AlCl3) for injection across biosensor surfaces. Binding curves for
wildtype RGS proteins and cysteine point-mutants of RGS4 were obtained at 20°C using 200
μl injections (using the KINJECT command) with a 200 second dissociation phase at 20 μl/
min. Non-specific binding to a denatured Gαi1-biotin surface was subtracted from each curve
(BIAevaluation software v3.0; Biacore).
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2.5 Förster resonance energy transfer (FRET)-based binding assays
Förster resonance energy transfer was used to measure binding interactions between Gαi1 and
RGS proteins as previously described [14]. Briefly, FRET between Gαi1-CFP and YFP-RGS
fusion proteins was measured using a SpectraMax Gemini 96-well plate fluorescence reader
(Molecular Devices; Sunnyvale, CA); association of Gαi1-CFP and YFP-RGS proteins induced
by the addition of aluminum tetrafluoride results in nonphotonic energy transfer and a
subsequent increase in emission at 528 nm relative to the emission at 480 nm. All runs were
conducted with excitation wavelength of 433 nm, a 455 nm cutoff filter, and emission scans
from 474 nm to 532 nm at 2 nm intervals. FRET was calculated as the ratio of emission at 528
nm / 480 nm. Binding assays were initiated by the addition of Gαi1-CFP and fluorescence was
measured within 2 minutes, given that reactions containing CCG-4986 did not appear to be
stable over long time periods.
2.6 Mass spectrometry
Sample Preparation: 39 nmol of RGS4 proteins were incubated in MS Buffer with a 15-
fold molar excess of CCG-4986 (30 mM in DMSO) for 5 minutes at room temperature and
then filtered on a 5 ml sephadex G-25 column (HiTrap Desalting Column; GE Healthcare) in
order to remove DMSO and excess CCG-4896.
Sample Analysis: Prior to mass spectrometric analyses, RGS4 protein samples were applied
to C4 ZipTip columns (Millipore, Billerica, MA) and eluted using 50% acetonitrile/2% acetic
acid. For intact molecular weight determination, 1 μl of each sample was analyzed by
electrospray ionization mass spectrometry (ESI-MS) on an ABI QSTAR-Pulsar QTOF mass
spectrometer fitted with a nanoelectrospray source (Proxeon Biosistems A/S, Odense,
Denmark). To determine the labeled sites of RGS4, tryptic digestions of untreated and
CCG-4986-treated RGS4 were performed. Digested samples were then applied to C18 ZipTips
and eluted with 50% acetonitrile/0.1% trifluoroacetic acid. 0.5 μl of each sample was mixed
with 0.5 μl matrix (a saturated solution of α–cyano-4-hydroxycinnamic acid in 50%
acetonitrile/0.1% trifluoroacetic acid) and analyzed by matrix-assisted laser desorption/
ionization mass spectrometry (MALDI-MS and MALDI-MS/MS fragmentation) on a Bruker
Ultraflex I mass spectrometer (Bruker Daltonics, Billerica, MA, USA). All mass spectrometric
data were gathered at the UNC-Duke Michael Hooker Proteomics Center (Chapel Hill, NC).
2.7 Molecular modeling
Model building using the RGS4/Gαi1 complex coordinates (PDB id 1AGR; ref. [18]) was
performed in the program O [19]. Structural images were made with PyMol (DeLano Scientific,
South San Francisco, CA).
3. Results and Discussion
3.1 CCG-4986 is a cysteine-dependent RGS4 inhibitor
In a desire to establish the structural determinants of CCG-4986 function as an RGS protein
inhibitor, we initiated crystallization trials towards obtaining a high-resolution structure of a
RGS4/CCG-4986 complex by x-ray diffraction. However, we found that admixture of
CCG-4986 with purified RGS4 protein solutions containing reducing agents (e.g.,
dithiothreitol [DTT]) led to an immediate generation of a bright yellow substance (data not
shown); this proved problematic to continued crystallization trials, as the purification of RGS4
in the absence of reducing agent resulted in a heterogenous mixture of monomer and dimers
(data not shown). Formation of this bright yellow reaction product, not reported in the original
paper by Roman and colleagues [12], was reproduced by exposing CCG-4986 to DTT. As
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CCG-4986 contains two sulfur atoms, we hypothesized that its mechanism of action could be
one of thiol reactivity and, hence, covalent modification of cysteine residue(s) in RGS4.
To highlight solvent-exposed residues within RGS4, a multiple sequence alignment of RGS
domains was created in combination with the GETAREA 1.1 algorithm for calculating
accessible surface area [20] as applied to the NMR structural coordinates of uncomplexed
RGS4 (PDB id 1EZT; ref. [21]). This alignment revealed two solvent-exposed cysteines
present within the RGS domain of RGS4 (Cys-71 and Cys-132, Fig. 1A). These two cysteines
within RGS4 are not conserved among other R4-subfamily RGS proteins; for example, the
corresponding residues in RGS8 are Tyr-65 and Gln-126 and in RGS16 are Asn-74 and
Glu-135 (Fig. 1A). To determine if the inhibitory activity of CCG-4986 was dependent on the
Cys-71 and/or Cys-132 residues unique to RGS4, mutant RGS4 proteins were purified (Fig.
1B) bearing Cys-71-to-Asn and/or Cys-132-to-Glu point mutations (based on the closely-
related RGS16 sequence; Fig. 1A) and subjected to biochemical analyses of RGS protein
function.
Assays of RGS4 GAP activity were initially performed using the fluorescent nucleotide analog
BODIPYFL-GTP [16]. Wildtype RGS4 stimulated the intrinsic GTPase activity of GαoA in a
dose-dependent manner (Fig. 2A). GAP activity was substantially diminished by preincubation
of wildtype RGS4 with 30 μM CCG-4986 (Fig. 2A). The double point-mutant RGS4(C71N/
C132E) also had potent GAP activity toward GαoA, but this activity was not inhibited by
preincubation with 30 μM CCG-4986 (Fig. 2B), thus demonstrating the requirement of a
cysteine residue in RGS4 for CCG-4986 bioactivity.
Surface plasmon resonance (SPR) was used to measure the ability of wildtype and mutant
RGS4 proteins to bind immobilized Gαi1 in its GDP/aluminum tetrafluoride-bound transition
state (the Gα nucleotide state bound most avidly by RGS proteins; ref. [22]). Addition of a 10-
fold molar excess of CCG-4986 completely abolished wildtype RGS4 binding to
Gαi1·GDP·AlF4- (Fig. 3A), but had no significant effect on Gαi1 binding by RGS8 and RGS16
proteins (Fig. 3B-C). Preincubation of CCG-4986 with DTT blocked its inhibitory action on
the RGS4/Gαi1 interaction (Fig. 3A); we believe this loss of inhibitory action is the result of a
DTT-induced reduction of CCG-4986. Mutation of the two solvent-exposed cysteines of RGS4
also resulted in a dramatic reduction in the inhibitory effect of CCG-4986 on the RGS4/Gαi1
interaction (Fig. 3D). To determine the individual roles of Cys-71 and Cys-132 in CCG-4986
activity, the single point-mutants of RGS4 were also profiled for Gαi1 binding using SPR. The
Cys-71-to-Asn mutant remained sensitive to inhibition by CCG-4986; as with wildtype RGS4,
this inhibitory effect was lost upon treatment of CCG-4986 with DTT (Fig. 3E). In contrast,
Gαi1 binding by the Cys-132-to-Glu mutant of RGS4 was unaffected by CCG-4986 (Fig. 3F).
These results suggest that Cys-132 is required for CCG-4986-mediated inhibition of Gαi1
binding by RGS4.
To confirm these SPR findings, we used an independent experimental approach of in vitro
FRET between CFP- and YFP-labeled fusion proteins to quantify RGS4/Gαi1 binding in the
presence of CCG-4986. We previously reported [14] that, upon interaction between YFP-RGS4
and Gαi1-CFP (the latter in its GDP/aluminum tetrafluoride-bound transition state), excitation
of CFP at 433 nm results in an increase in acceptor (YFP) emission at 528 nm and a
corresponding decrease in donor (CFP) emission at 480 nm. The ratio of emissions at 528 nm
and 480 nm can thus be used to quantify binding between RGS4 and Gαi1 [14]. We observed
a concentration-dependent reduction in FRET between YFP-RGS4 and transition-state Gαi1-
CFP upon the addition of CCG-4986 (Fig. 4A). Similarly, addition of CCG-4986 to YFP-RGS4
(C71N) reduced observed FRET (Fig. 4B), while the addition of solvent alone (DMSO) had
no inhibitory effect on FRET from either protein pairing (Fig. 4A,B). In contrast, no reduction
in FRET was seen upon addition of CCG-4986 to YFP-RGS4(C132E) or YFP-RGS4(C71N,
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C132E) proteins (Fig. 4C,D). To confirm that the interaction between transition state Gαi1-
CFP and YFP-RGS4 was reversible, unlabeled RGS4 was used as a positive control for
inhibition (Fig. 4C,D).
Our BODIPYFL-GTP hydrolysis, SPR, and FRET data all confirmed previously published
findings describing CCG-4986 as a selective inhibitor of the RGS4/Gα binding interaction and
of RGS4 GAP activity on Gαo [12]; our analysis of cysteine point-mutants of RGS4 further
demonstrated that Cys-132 is necessary for the inhibitory activity of CCG-4986. To confirm
that CCG-4986 inhibition of RGS4-mediated GAP activity required the Cys-132 residue within
RGS4, we repeated in vitro GAP assays using radiolabeled GTP as previously described
[17]. Calculated initial rates of [γ−32P]GTP hydrolysis from these single-turnover assays were
as follows: Gα alone, 0.011 s−1; Gα + RGS4(wildtype), 0.21 s−1; Gα + RGS4(wildtype) +
CCG-4986, 0.074 s−1; Gα + RGS4(C132E), 0.044 s−1; Gα + RGS4(C132E) + CCG-4986,
0.036 s−1. The Cys-132-to-Glu mutation reduced the GAP activity of RGS4 (4-fold increase
in initial GTP hydrolysis rate vs 19-fold for wildtype RGS4); this reduced GAP activity could
be the result of some degree of steric hindrance to the binding of Gα substrate given the
replacement of cysteine with a charged, more bulky residue of glutamate. However, this mutant
RGS protein was clearly still active as an accelerator of Gα GTP hydrolysis and not
significantly inhibited by preincubation with a 10-fold molar excess CCG-4986 (18% reduction
in GAP activity vs 65% reduction of wildtype RGS4 GAP activity). These results again
highlight the requirement of the Cys-132 residue in RGS4 to CCG-4986 inhibitory activity.
3.2 CCG-4986 covalently modifies RGS4 cysteine residues
To unambiguously determine if CCG-4986 is a covalent modifier of RGS4, intact molecular
weight determinations of unreacted and CCG-4986-treated RGS4 protein samples were
performed by nano-ESI-MS. Compared to unreacted RGS4 protein (Fig. 5A), CCG-4986-
treated RGS4 protein revealed three prominent forms (Fig. 5B), with molecular weights that
correspond to wildtype RGS4 (19,743 Da), RGS4 plus one 153 Da substituent (19,896 Da),
and RGS4 plus two 153 Da substituents (20,050 Da). To identify specific reaction sites, tryptic
digestion of unreacted and CCG-4986-treated RGS4 protein samples was performed, followed
by MALDI-MS detection of tryptic peptide fragments. Two tryp tic peptides, T13 (amino acids
59-WAESLENLISHECGLAAFK-77) and T23 (amino acids 126-EVNLDSCTR-134), that
contain Cys-71 and Cys-132, respectively, were found to have an increased mass of 153 Da in
the CCG-4986 treated sample (data not shown). MS/MS data from peptide fragmentation
confirmed that the molecular mass modification reaction arising from CCG-4986 treatment
occurred specifically on Cys-71 and Cys-132 residues (data not shown). While such MS/MS
analysis does not define the structure of the attached moiety, it most likely represents a fragment
of CCG-4986 covalently bonded to a cysteine via a disulfide bond (Fig. 5C). We hypothesize
that the attached fragment is a 4-nitrobenzenethiol radical (MW 154.17) derived from
breakdown of CCG-4986. Formation of a disulfide bond by this reacting fragment of
CCG-4986 would result in the loss of a hydrogen atom from the thiol of cysteine (1.0 Da) and
account for the observed 153 Da moiety observed as a covalent substituent on Cys-71 and
Cys-132 residues.
3.3 RGS8 inhibition by CCG-4986 upon to mutation of glutamine-126 to cysteine
To test whether a cysteine residue at position 132 of RGS4 was sufficient for CCG-4986
sensitivity, we mutated the analogous position within RGS8 (glutamine-126; Fig. 1A) to
cysteine in the context of the YFP-RGS protein fusion and tested both wildtype and RGS8
(Q126C) proteins using the in vitro FRET assay for Gα binding. While wildtype YFP-RGS8
was insensitive to CCG-4986 inhibition, as previously described (Fig. 3 and ref. [12]), the YFP-
RGS8(Q126C) fusion protein was inhibited in a dose-dependent fashion by CCG-4986 (Fig.
6).
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3.4 Structural basis of RGS4 inhibition by CCG-4986
From the atomic resolution structure of the RGS4/Gαi1 complex [18], it is apparent that
covalent addition of a 153 Da 4-nitrobenzenethiol moiety to the Cys-132 residue of RGS4
would cause significant steric hindrance to the binding of Gα. Specifically, the addition of a
CCG-4986 fragment is predicted to result in van der Waals collisions with Arg-86 and Arg-90
residues of the all-helical domain of Gαi1 (Fig. 7). Hence, from the biochemical and mass
spectrometry data presented above, our conclusion is that the most likely mechanism for the
inhibitory properties of CCG-4986 is non-specific modification of surface-exposed cysteine
residues in RGS4 causing a steric inhibition of the RGS4/Gαi1 interaction. While reactive
inhibitors have made widely successful drugs (e.g., aspirin, clopidogrel; refs. [23,24]), the lack
of selectivity of CCG-4986 for cysteines on RGS4 suggests that CCG-4986 will react with
surface-exposed cysteines in a myriad of proteins beyond its intended RGS protein target.
Furthermore, although Roman and colleagues have speculated that the lack of CCG-4986
activity on intact RGS4-transfected cells is a result of poor membrane permeability [12], it is
more likely that the requirement for cell membrane permeabilization to observe the effects of
CCG-4986 reflects sensitivity to a reducing environment such as that found inside intact cells.
These predictions as to the labile and reactive nature of CCG-4986 bode ill for its further
development as a lead chemical entity for RGS protein-directed pharmacotherapy.
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Multiple sequence alignment of human R4-subfamily RGS proteins RGS4, −8, −16, and the
RZ-subfamily member RGS19. (A) Solvent-accessible residues within RGS4 are demarcated
by “o” (outside), while internal residues are noted by “i” (inside) and partially solvent-exposed
residues are unlabeled, as predicted by the GETAREA 1.1 algorithm [20] using a solvent probe
of 1.40 Å as applied to the high-resolution structure of free RGS4 [21]. Position of Cys-71 and
Cys-132, found uniquely within RGS4, are indicated by arrowheads. Alpha-helices observed
within the NMR structures of RGS4 and RGS19 [21,25] are numbered in Roman numerals.
(B) Equivalent purification of wildtype and cysteine point-mutant RGS4 and RGS8 proteins
for biochemical and mass spectrometry analyses is highlighted by coomassie blue staining of
SDS-PAGE resolved proteins.
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In vitro assays of RGS4 GAP activity. Single nucleotide binding-and-hydrolysis assays were
conducted to measure acceleration of GαoA GTP hydrolysis rate by (A) wildtype and (B)
cysteine-substituted (C71N/C132E) forms of RGS4. The fluorescence of 50 nM BODIPYFL-
GTP was measured at 20 °C in 1 ml of buffer containing various concentrations of RGS4
protein (0 to 5 μM) previously incubated for 2 minutes with 30 μM CCG-4986 or DMSO
vehicle only. Fluorescence measurements were initiated and, at 60 seconds, GαoA (100 nM)
was added to cuvettes. Normalized GAP activity was then calculated as described [16] and
plotted on the ordinate versus RGS4 concentration on the abscissa.
Kimple et al. Page 10














Surface plasmon resonance-based Gα-binding assays analyzing the inhibitory properties of
CCG-4986 on wildtype RGS4 (A), RGS8 (B), RGS16 (C), and indicated cysteine mutants of
RGS4 (panels D-F). 6000 resonance units (RU) of biotin-Gαi1 protein was immobilized on a
streptavidin biosensor surface. A 200 μl aliquot of 5 μM RGS protein, previously incubated
with either DMSO vehicle (black), CCG-4986 (gray), or DTT-reduced CCG-4986 (dotted
gray), was injected at 20 μl/min (0 to 600 seconds) with a follow-up 200 seconds of dissociation
time in running buffer only (600 to 800 seconds).
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Competition FRET assays of the Gαi1-CFP /YFP-RGS4 interaction. (A) Addition of increasing
concentrations of CCG-4986 inhibitor to 200 nM Gαi1-CFP and 280 nM YFP-RGS4, in buffer
containing aluminum tetrafluoride (AMF), decreased the 528 nm/ 480 nm emission ratio,
indicating a decrease in the RGS4/Gαi1 interaction. Neither mock treatment with DMSO
vehicle alone nor addition of CCG-4986 in GDP-containing buffer (i.e., lacking aluminum
tetrafluoride) resulted in a significant change in the FRET ratio, indicating that competition is
caused specifically by CCG-4986. While a covalent reaction cannot be characterized by
traditional pharmacological analysis (i.e., IC50 or Ki calculations), the signal was seen to be
reduced by 50% at 18 μM CCG-4986. (B) Analogous to wildtype YFP-RGS4, the YFP-RGS4
(C71N) mutant displayed a dose-dependent decrease in the emission ratio, indicating the ability
of CCG-4986 to act as an inhibitor of its association with Gαi1-CFP. 50% inhibition was
achieved at 4 μM CCG-4986. No inhibitory effect was seen as the result of DMSO treatment
alone. (C) Increasing amounts of CCG-4986 had no inhibitory effects on the interaction
between the C71N/C132E double mutant of YFP-RGS4 (560 nM) and 400 nM Gαi1-CFP in
its aluminum tetrafluoride-loaded form. Unlabeled RGS4, added as a positive control for
competitive inhibition of YFP-RGS4 binding, was able to decrease the emission ratio as
expected (IC50 value of 375 nM; 95% confidence interval of 300−470 nM). (D) As with the
double mutant, the inhibitory effects of CCG-4986 were abolished upon mutating solely the
cysteine-132 of YFP-RGS4. To confirm that this single cysteine mutation did not alter the
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sensitivity of the assay to detect inhibition, unlabeled RGS4 was used as a competitor and
found to have an IC50 of 284 nM (95% C.I. of 200−410 nM). All samples in all panels were
performed in triplicate, with error bars representing the mean ± SEM.
Kimple et al. Page 13














Intact molecular weight determination of unreacted and CCG-4986 treated RGS4. (A)
Untreated RGS4 was found to exist in a single dominant form corresponding to its predicted
molecular weight. (B) RGS4 preincubated with CCG-4986 was found in to consist of three
major forms. The three peaks obtained by nano-ESI-MS correspond to the molecular weight
of RGS4 (19,743 Da), RGS4 + 153 Da (19,896 Da), and RGS4 + 2×(153 Da) (20,050 Da). (C)
CCG-4986 (methyl-N-[(4-chlorophenyl)sulfonyl]-4-nitrobenzenesulfinimidoate) has two
sulfur atoms that potentially could react with thiol groups of solvent-exposed cysteine residues.
Based on the mass spectrometry data from CCG-4986-treated RGS4, we propose that the 4-
nitrobenzenethiol group is covalently attached to the two surface-exposed cysteines Cys-71
Kimple et al. Page 14













and Cys-132 in RGS4. The mass of the disulfide-bonded adduct derived from CCG-4986 would
correspond precisely with the MS peaks at 19,896 Da (RGS4 + one 4-nitrobenzenethiol group)
and 20,050 Da (RGS4 + two 4-nitrobenzenethiol groups).
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Competition FRET assays of the Gαi1-CFP / YFP-RGS8 interaction. (A) Addition of increasing
concentrations of CCG-4986 inhibitor to 400 nM Gαi1-CFP and 560 nM YFP-RGS4, in buffer
containing aluminum tetrafluoride (AMF), did not decrease the 528 nm/ 480 nm emission ratio,
indicating that CCG-4986 does not decrease the RGS8/Gαi1 interaction. Unlabeled RGS8 was
added as a positive control for competitive inhibition of YFP-RGS8 binding and was able to
decrease the emission ratio as expected (IC50 value of 352 nM; 95% confidence interval of
307−403 nM). Addition of CCG-4986 in GDP-containing buffer did not result in a significant
change of FRET. (B) The YFP-RGS8(Q126C) / Gαi1-CFP interaction was decreased in a dose-
dependent manner upon the addition of CCG-4986. 50% inhibition was observed at 1.9 μM.
Neither treatment with DMSO vehicle alone nor addition of CCG-4986 in GDP-containing
buffer resulted in significant change in the FRET ratio, indicating that RGS8(Q126C) was
inhibited specifically by CCG-4986. All samples in all panels were performed in triplicate,
with error bars representing the mean ± SEM.
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Proposed model for RGS4 inhibition by CCG-4986. The presence of the cysteine-132 residue
of RGS4 is clearly necessary for the inhibitory action of CCG-4986. While cysteine-132 is not
critical for the RGS4/Gα interaction per se (i.e., its conversion to glutamate does not eliminate
GAP activity [Fig. 2] nor Gα association [Figs. 3 & 4]), the known high-resolution structure
of the RGS4/Gαi1 complex [18] suggests that a small moiety (purple) covalently coupled to
Cys-132 (orange) would result in steric hindrance with the Arg-86 and Arg-90 (light gray) of
the all-helical domain of Gαi1 (steel blue). The Cα ribbon trace of RGS4 is illustrated in
green; GDP bound within the G-protein is colored in wheat, with the aluminum tetrafluoride
ion in light blue and gray.
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